Skip to main content


Volume 447: debated on Thursday 22 June 2006

To ask the Secretary of State for Health pursuant to her answer of 4 April 2006, Official Report, column 123W, on influenza, what she expects the expanded production capacity will be in the UK. (67038)

The expansion of manufacturing capacity is an ongoing process. Much depends on research and development results. One promising approach is the incorporation of adjuvants (agents to enhance the immune response), thereby allowing smaller quantities of the vaccine itself to be used, expanding the numbers of available doses. The Department is in close touch with both industry development plans and the international initiatives to increase vaccine manufacturing capacity.